Table 2 Changes in BMI and body weight before and after the follow-up.
From: Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease
Outcomes | iMAO-Bi group, (N = 23) | Control group, (N = 14) | Intergroup difference, (95% CI) | P |
|---|---|---|---|---|
BMI (kg/m2) | ||||
ANCOVAa | ||||
Follow-up BMI with adjusted baselineb | 23.91 (23.38, 24.44) | 23.97 (23.14, 24.81) | −0.07 (−1.08, 0.96) | 0.897 |
Two Independent sample t-test | ||||
Baseline BMI | 24.73 (23.49, 25.97) | 22.79 (20.56, 25.03) | 0.090 | |
Follow-up BMI | 24.68 (23.37, 25.99) | 22.77 (20.49, 25.05) | 0.390 | |
Change from baseline in BMI | −0.06 (−0.58, 0.47) | −0.02 (−0.72, 0.67) | −0.03 (−0.87, 0.80) | 0.936 |
Bodyweight (kg) | ||||
ANCOVAc | ||||
Follow-up bodyweight with adjusted baselined | 66.38 (64.92, 67.84) | 66.60 (64.32, 68.89) | −0.22 (−2.97, 2.52) | 0.868 |
Two Independent sample t-test | ||||
Baseline body weight | 67.68 (63.44, 72.13) | 64.46 (56.80, 72.13) | 0.395 | |
Follow-up bodyweight | 67.76 (62.87, 72.66) | 64.57 (57.01, 72.13) | 0.439 | |
Change from baseline in body weight | −0.02 (−1.49, 1.45) | 0.11 (−1.82, 2.03) | −0.13 (−2.46, 2.20) | 0.911 |
